The publication of full trial results from the MANDARA trial further underlines the potential of benralizumab (Fasenra) in the ability to help adult patients achieve remission of relapsing or refractory eosinophilic granulomatosis with polyangiitis.
CU Anschutz
Academic Office One
12631 East 17th Avenue
8601
Aurora, CO 80045